Tocilizumab use in Kidney Transplant Patients with COVID-19.
Identifieur interne : 000D48 ( Main/Corpus ); précédent : 000D47; suivant : 000D49Tocilizumab use in Kidney Transplant Patients with COVID-19.
Auteurs : Hernando Trujillo ; Fernando Caravaca-Fontán ; Ángel Sevillano ; Eduardo Gutiérrez ; Mario Fernández-Ruiz ; Francisco L Pez-Medrano ; Ana Hernández ; José María Aguado ; Manuel Praga ; Amado AndrésSource :
- Clinical transplantation [ 1399-0012 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antibodies, Monoclonal, Humanized (therapeutic use), COVID-19 (drug therapy), COVID-19 (etiology), Female (MeSH), Follow-Up Studies (MeSH), Hospitalization (MeSH), Humans (MeSH), Immunologic Factors (therapeutic use), Kidney Transplantation (MeSH), Male (MeSH), Middle Aged (MeSH), Postoperative Complications (drug therapy), Retrospective Studies (MeSH), Severity of Illness Index (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Immunologic Factors.
- drug therapy : COVID-19, Postoperative Complications.
- etiology : COVID-19.
- Adult, Aged, Female, Follow-Up Studies, Hospitalization, Humans, Kidney Transplantation, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Treatment Outcome.
Abstract
A potential benefit of immunomodulatory agents such as tocilizumab (TCZ) has been reported in patients with coronavirus disease 2019 (COVID-19) and severe pulmonary involvement. However, this therapy has been scarcely studied in kidney transplant (KT) recipients. Herein, we describe the clinical course and outcome of 10 KT patients with severe COVID-19 that were treated with TCZ. Mean age of the study group was 54 ± 10 years (70% females), and 30% of the cases were within 6 months from transplant. Mycophenolate mofetil was discontinued in all cases upon admission, whereas baseline steroids were maintained and tacrolimus dose was reduced. Initial treatment included hydroxychloroquine, antibiotics, and prophylactic anticoagulation. Before treatment with TCZ, 3 patients were receiving high-flow oxygen, 4 patients low-flow oxygen and 1 case non-invasive ventilation. All patients received a single dose of intravenous TCZ within a mean time of 7 ± 4 days since admission. During a median follow-up of 16 days (IQR: 10-29), 7 patients (70%) gradually improved and were finally discharged while three cases (30%) did not exhibited clinical improvement and ultimately died. In conclusion, although treatment with TCZ could be associated with improved clinical outcomes in a subset of KT recipients with COVID-19, further studies are warranted before drawing firm conclusions.
DOI: 10.1111/ctr.14072
PubMed: 32862472
Links to Exploration step
pubmed:32862472Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tocilizumab use in Kidney Transplant Patients with COVID-19.</title><author><name sortKey="Trujillo, Hernando" sort="Trujillo, Hernando" uniqKey="Trujillo H" first="Hernando" last="Trujillo">Hernando Trujillo</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Caravaca Fontan, Fernando" sort="Caravaca Fontan, Fernando" uniqKey="Caravaca Fontan F" first="Fernando" last="Caravaca-Fontán">Fernando Caravaca-Fontán</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Sevillano, Angel" sort="Sevillano, Angel" uniqKey="Sevillano A" first="Ángel" last="Sevillano">Ángel Sevillano</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Gutierrez, Eduardo" sort="Gutierrez, Eduardo" uniqKey="Gutierrez E" first="Eduardo" last="Gutiérrez">Eduardo Gutiérrez</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fernandez Ruiz, Mario" sort="Fernandez Ruiz, Mario" uniqKey="Fernandez Ruiz M" first="Mario" last="Fernández-Ruiz">Mario Fernández-Ruiz</name><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="L Pez Medrano, Francisco" sort="L Pez Medrano, Francisco" uniqKey="L Pez Medrano F" first="Francisco" last="L Pez-Medrano">Francisco L Pez-Medrano</name><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Hernandez, Ana" sort="Hernandez, Ana" uniqKey="Hernandez A" first="Ana" last="Hernández">Ana Hernández</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Aguado, Jose Maria" sort="Aguado, Jose Maria" uniqKey="Aguado J" first="José María" last="Aguado">José María Aguado</name><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Praga, Manuel" sort="Praga, Manuel" uniqKey="Praga M" first="Manuel" last="Praga">Manuel Praga</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Andres, Amado" sort="Andres, Amado" uniqKey="Andres A" first="Amado" last="Andrés">Amado Andrés</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32862472</idno><idno type="pmid">32862472</idno><idno type="doi">10.1111/ctr.14072</idno><idno type="wicri:Area/Main/Corpus">000D48</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tocilizumab use in Kidney Transplant Patients with COVID-19.</title><author><name sortKey="Trujillo, Hernando" sort="Trujillo, Hernando" uniqKey="Trujillo H" first="Hernando" last="Trujillo">Hernando Trujillo</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Caravaca Fontan, Fernando" sort="Caravaca Fontan, Fernando" uniqKey="Caravaca Fontan F" first="Fernando" last="Caravaca-Fontán">Fernando Caravaca-Fontán</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Sevillano, Angel" sort="Sevillano, Angel" uniqKey="Sevillano A" first="Ángel" last="Sevillano">Ángel Sevillano</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Gutierrez, Eduardo" sort="Gutierrez, Eduardo" uniqKey="Gutierrez E" first="Eduardo" last="Gutiérrez">Eduardo Gutiérrez</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fernandez Ruiz, Mario" sort="Fernandez Ruiz, Mario" uniqKey="Fernandez Ruiz M" first="Mario" last="Fernández-Ruiz">Mario Fernández-Ruiz</name><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="L Pez Medrano, Francisco" sort="L Pez Medrano, Francisco" uniqKey="L Pez Medrano F" first="Francisco" last="L Pez-Medrano">Francisco L Pez-Medrano</name><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Hernandez, Ana" sort="Hernandez, Ana" uniqKey="Hernandez A" first="Ana" last="Hernández">Ana Hernández</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Aguado, Jose Maria" sort="Aguado, Jose Maria" uniqKey="Aguado J" first="José María" last="Aguado">José María Aguado</name><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Praga, Manuel" sort="Praga, Manuel" uniqKey="Praga M" first="Manuel" last="Praga">Manuel Praga</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Andres, Amado" sort="Andres, Amado" uniqKey="Andres A" first="Amado" last="Andrés">Amado Andrés</name><affiliation><nlm:affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Research Institute Hospital, Madrid, Spain.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical transplantation</title><idno type="eISSN">1399-0012</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (etiology)</term><term>Female (MeSH)</term><term>Follow-Up Studies (MeSH)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Immunologic Factors (therapeutic use)</term><term>Kidney Transplantation (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Postoperative Complications (drug therapy)</term><term>Retrospective Studies (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Hospitalization</term><term>Humans</term><term>Kidney Transplantation</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A potential benefit of immunomodulatory agents such as tocilizumab (TCZ) has been reported in patients with coronavirus disease 2019 (COVID-19) and severe pulmonary involvement. However, this therapy has been scarcely studied in kidney transplant (KT) recipients. Herein, we describe the clinical course and outcome of 10 KT patients with severe COVID-19 that were treated with TCZ. Mean age of the study group was 54 ± 10 years (70% females), and 30% of the cases were within 6 months from transplant. Mycophenolate mofetil was discontinued in all cases upon admission, whereas baseline steroids were maintained and tacrolimus dose was reduced. Initial treatment included hydroxychloroquine, antibiotics, and prophylactic anticoagulation. Before treatment with TCZ, 3 patients were receiving high-flow oxygen, 4 patients low-flow oxygen and 1 case non-invasive ventilation. All patients received a single dose of intravenous TCZ within a mean time of 7 ± 4 days since admission. During a median follow-up of 16 days (IQR: 10-29), 7 patients (70%) gradually improved and were finally discharged while three cases (30%) did not exhibited clinical improvement and ultimately died. In conclusion, although treatment with TCZ could be associated with improved clinical outcomes in a subset of KT recipients with COVID-19, further studies are warranted before drawing firm conclusions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32862472</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>11</Month></PubDate></JournalIssue><Title>Clinical transplantation</Title><ISOAbbreviation>Clin Transplant</ISOAbbreviation></Journal><ArticleTitle>Tocilizumab use in Kidney Transplant Patients with COVID-19.</ArticleTitle><Pagination><MedlinePgn>e14072</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.14072</ELocationID><Abstract><AbstractText>A potential benefit of immunomodulatory agents such as tocilizumab (TCZ) has been reported in patients with coronavirus disease 2019 (COVID-19) and severe pulmonary involvement. However, this therapy has been scarcely studied in kidney transplant (KT) recipients. Herein, we describe the clinical course and outcome of 10 KT patients with severe COVID-19 that were treated with TCZ. Mean age of the study group was 54 ± 10 years (70% females), and 30% of the cases were within 6 months from transplant. Mycophenolate mofetil was discontinued in all cases upon admission, whereas baseline steroids were maintained and tacrolimus dose was reduced. Initial treatment included hydroxychloroquine, antibiotics, and prophylactic anticoagulation. Before treatment with TCZ, 3 patients were receiving high-flow oxygen, 4 patients low-flow oxygen and 1 case non-invasive ventilation. All patients received a single dose of intravenous TCZ within a mean time of 7 ± 4 days since admission. During a median follow-up of 16 days (IQR: 10-29), 7 patients (70%) gradually improved and were finally discharged while three cases (30%) did not exhibited clinical improvement and ultimately died. In conclusion, although treatment with TCZ could be associated with improved clinical outcomes in a subset of KT recipients with COVID-19, further studies are warranted before drawing firm conclusions.</AbstractText><CopyrightInformation>© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trujillo</LastName><ForeName>Hernando</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3520-1422</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caravaca-Fontán</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5830-9663</Identifier><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevillano</LastName><ForeName>Ángel</ForeName><Initials>Á</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutiérrez</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Ruiz</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Institute Hospital, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Medrano</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5333-7529</Identifier><AffiliationInfo><Affiliation>Research Institute Hospital, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>José María</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Research Institute Hospital, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Infectious Diseases, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praga</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute Hospital, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrés</LastName><ForeName>Amado</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute Hospital, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CP 18/00073</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Clin Transplant</MedlineTA><NlmUniqueID>8710240</NlmUniqueID><ISSNLinking>0902-0063</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="Y">kidney transplantation</Keyword><Keyword MajorTopicYN="Y">outcomes</Keyword><Keyword MajorTopicYN="Y">severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="Y">tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32862472</ArticleId><ArticleId IdType="doi">10.1111/ctr.14072</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19). JAMA. 2020;323(18):1824-1836.</Citation></Reference><Reference><Citation>Trujillo H, Caravaca-Fontán F, Sevillano Á, et al. SARS-CoV-2 infection in hospitalized patients with kidney disease. Kidney Int Rep. 2020;5(6):905-909.</Citation></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411-2418.</Citation></Reference><Reference><Citation>Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787-1799.</Citation></Reference><Reference><Citation>Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117:10970-10975.</Citation></Reference><Reference><Citation>Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO2/FiO2 ratio and the PaO2 /FiO2 ratio in patients with acute lung injury or ARDS. Chest. 2007;132(2):410-417.</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.</Citation></Reference><Reference><Citation>Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.</Citation></Reference><Reference><Citation>Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.</Citation></Reference><Reference><Citation>Shin B-H, Everly MJ, Zhang H, et al. Impact of Tocilizumab (Anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation. 2020;104:856-863.</Citation></Reference><Reference><Citation>Choi J, Aubert O, Vo A, et al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17:2381-2389.</Citation></Reference><Reference><Citation>Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813-822.</Citation></Reference><Reference><Citation>Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088.</Citation></Reference><Reference><Citation>Kojima T, Yabe Y, Kaneko A, et al. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol. 2013;23:977-985.</Citation></Reference><Reference><Citation>Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalised patients with COVID-19: A retrospective cohort study in a UK secondary care setting. Clin Microbiol Infect. 2020;26(10):1395-1399.</Citation></Reference><Reference><Citation>Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna K, Akbik B. Tocilizumab for treatment of patients with severe COVID19: a retrospective cohort study. EClinicalMedicine. 2020;24:100418.</Citation></Reference><Reference><Citation>Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32862472
|texte= Tocilizumab use in Kidney Transplant Patients with COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32862472" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |